Search

Running any research project is a feat of logistical gymnastics – and often, you don’t know what can go wrong until it happens.

Cutting-edge work is offering new hope to children with Cystic Fibrosis.

Patricia Ilchuk can still recall the day in August 2020 when her daughter Manna – then five weeks old – had her first seizure.

Findings from the Banksia Hill Project revealed 89% of young people in detention who were assessed as part of the project had at least one form of severe neurodevelopmental impairment.

Researchers have made a world-first discovery on how to prevent severe respiratory infections in babies.

Research

Meningococcal disease is caused by the bacteria Neisseria meningitidis, or 'meningococcus'. It is an uncommon but very serious disease that can result in death if not recognised and treated quickly.

Research

Although essential for overall health and wellbeing, little is known about skin health in urban-living Australian Aboriginal children. This co-designed, research-service project aimed to describe skin health and document skin disease frequency in urban-living Aboriginal children and young people in Western Australia and investigate housing associations for skin infections.

Research

Malaria imposes a significant global health burden and remains a major cause of child mortality in sub-Saharan Africa. In many countries, malaria transmission varies seasonally. The use of seasonally-deployed interventions is expanding, and the effectiveness of these control measures hinges on quantitative and geographically-specific characterisations of malaria seasonality.

Research

Evidence suggests that the earlier supports are provided to young Autistic children, the better the overall outcomes. Supports have typically only been available after an autism diagnosis but with increased knowledge about early developmental trajectories, clinical supports can now be offered prediagnosis for infants showing early autism features and/or those with a family history of autism. 

Research

The World Health Organization recommends perennial malaria chemoprevention (PMC), generally using sulfadoxine-pyrimethamine (SP) to children at high risk of severe Plasmodium falciparum malaria. Currently, PMC is given up to age two in perennial transmission settings. However, no recommendation exists for perennial settings with seasonal variation in transmission intensity, recently categorized as 'sub-perennial'.